Abstract
The paper gives the results of evaluating the efficiency of deINS1 pandemic H5N1 vaccine candidate VN1203delNS1 which was constructed by reverse genetics on the basis of influenza virus strain A/Vietnam/1203/04. The safety, immunogenicity and cross-protection of the vaccine strain against different H5N1 virus clades were demonstrated in mouse and macaque models. The results showed the possibility of designing a new-generation replication-deficient intranasal influenza vaccine, by applying an approach to deleting the NS1 pathogenicity factor, an antagonist of the interferon system.
MeSH terms
-
Administration, Intranasal
-
Animals
-
Chlorocebus aethiops
-
Cross Protection / immunology
-
Drug Evaluation, Preclinical
-
Humans
-
Influenza A Virus, H5N1 Subtype / genetics*
-
Influenza A Virus, H5N1 Subtype / immunology
-
Influenza Vaccines / genetics
-
Influenza Vaccines / immunology
-
Influenza Vaccines / therapeutic use*
-
Influenza, Human / genetics
-
Influenza, Human / immunology
-
Influenza, Human / prevention & control*
-
Interferons / metabolism
-
Macaca fascicularis
-
Mice
-
Orthomyxoviridae Infections / genetics
-
Orthomyxoviridae Infections / immunology
-
Orthomyxoviridae Infections / prevention & control*
-
Reverse Genetics / methods
-
Vaccines, Attenuated / genetics
-
Vaccines, Attenuated / immunology
-
Vaccines, Attenuated / therapeutic use*
-
Vero Cells
-
Viral Nonstructural Proteins / genetics*
-
Viral Nonstructural Proteins / immunology
Substances
-
Influenza Vaccines
-
Vaccines, Attenuated
-
Viral Nonstructural Proteins
-
Interferons